Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)

<Previous Article In Volume
Next Article In Volume>

Tramiprosate as a Novel Treatment for Mild-Moderate Alzheimer Disease

A Systematic Review

Authors
Abiyyu Didar Haq1, Visakha Vidyadevi Wiguna1, Putu Diah Ananda Putri Atmaja1, Cut Warnaini2, *
1Faculty of Medicine, University of Mataram
2Department of Public Health, Faculty of Medicine, University of Mataram
*Corresponding author. Email: cut.warnaini@unram.ac.id
Corresponding Author
Cut Warnaini
Available Online 21 February 2022.
DOI
10.2991/ahsr.k.220206.049How to use a DOI?
Keywords
Alzheimer Disease; Clinical Outcome; Tramiprosate
Abstract

Alzheimer Disease (AD) is a chronic neurodegenerative disease. Currently, treatment for AD is limited to symptomatic treatment only, which are cholinesterase inhibitor and memantine. Acting as a symptomatic treatment, those drugs don’t act on the pathogenesis of AD. Tramiprosate is a small aminosulfate substance which able to decrease the aggregation of amyloid plaque. Currently there are plenty of studies regarding its effectiveness for the treatment of AD, yet reviews regarding this topic are still lacking to analyze the effect of tramiprosate on clinical outcomes of mild to moderate Alzheimer disease (AD) patients. A systematic review was conducted based on PRISMA through PubMed, ScienceDirect, and CENTRAL, searching for randomized controlled trials which analyze tramiprosate’s effects on clinical outcomesof mild to moderate AD patients. Studies selected were then assessed for bias risk with CONSORT criteria. The search yielded six RCTs with a total of 6.346 subjects. Tramiprosate intervention is proven to be effective in reducing ADAS-cog and CBR-SB score while decreasing the decline of hippocampus volume significantly. Furthermore, there are another clinical benefit, such as increasing DAD and cognitive function that showed a positive trend. To conclude, tramiprosate showed promising results to be widely implemented as treatment for mild to moderate AD patients.

Copyright
© 2022 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)
Series
Advances in Health Sciences Research
Publication Date
21 February 2022
ISBN
10.2991/ahsr.k.220206.049
ISSN
2468-5739
DOI
10.2991/ahsr.k.220206.049How to use a DOI?
Copyright
© 2022 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Cite this article

risenwbib
TY  - CONF
AU  - Abiyyu Didar Haq
AU  - Visakha Vidyadevi Wiguna
AU  - Putu Diah Ananda Putri Atmaja
AU  - Cut Warnaini
PY  - 2022
DA  - 2022/02/21
TI  - Tramiprosate as a Novel Treatment for Mild-Moderate Alzheimer Disease
BT  - Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)
PB  - Atlantis Press
SP  - 265
EP  - 270
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.220206.049
DO  - 10.2991/ahsr.k.220206.049
ID  - Haq2022
ER  -